置管天数作为儿童隧道式股静脉经外周静脉置入中心静脉导管相关血流感染的决定因素
研究纳入445例患儿共573次隧道式股静脉PICC置管,累计14,855个导管日,发生20例非黏膜屏障损伤相关CLABSI(1.35/1000导管日);置管30天内CLABSI率为0.51/1000导管日,低于30天后的3.06/1000导管日,统计模型显示CLABSI日风险从第1天至第30天快速上升,此后维持高位。
要点
- 隧道式股静脉PICC置管30天内CLABSI率为0.51/1000导管日,30天后升至3.06/1000导管日。
- NICU置管CLABSI率最高(2.01/1000导管日),介入放射科最低(0.26/1000导管日)。
- 统计模型显示CLABSI日风险从第1天至第30天快速上升,之后维持高位。
核心结论
- 隧道式股静脉PICC是相对安全有效的中心静脉通路替代方案,但CLABSI发生率似乎随置管天数增加而快速上升直至约第30天,此后维持高位。
研究设计与样本
- 研究纳入2017年1月1日至2020年1月31日期间445例患儿(196女,249男;中位年龄49.4天;中位体重3.7 kg)的573次隧道式股静脉PICC置管或更换,所有导管在超声引导下置入,采用加速失效时间模型(指数、Weibull和对数正态分布)分析CLABSI随时间发生的概率。
诊断标准与关键数值
- CLABSI仅计入非黏膜屏障损伤相关感染,依据美国疾病控制与预防中心(CDC)定义;隧道式股静脉PICC置管共14,855个导管日,发生20例CLABSI(1.35/1000导管日);NICU置管CLABSI率2.01/1000导管日,介入放射科置管0.26/1000导管日,介入放射科以外置管1.72/1000导管日;置管30天内CLABSI率0.51/1000导管日,30天后3.06/1000导管日。
临床应用与阅片要点
- 作者认为隧道式股静脉PICC是相对安全有效的中心静脉通路替代方案,但CLABSI发生率似乎随置管天数增加而快速上升直至约第30天,此后维持高位;原文未据此给出具体阅片或报告推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Ultrasound (US)-guided tunneled femoral peripherally inserted central catheters (PICCs) are a safe central venous access option in infants and neonates. Studies have shown, however, that femoral central venous access has the potential for high central line-associated bloodstream infection (CLABSI) rates with a significant increase in risk around line day 30, though no studies have evaluated these risks exclusively for tunneled femoral PICCs.
OBJECTIVE: The primary purpose of this study was to evaluate the relationship between line duration and the risk of CLABSI in tunneled femoral PICCs in children.
MATERIALS AND METHODS: Four hundred forty-five patients (196 females, 249 males; median age: 49.4 days; median weight: 3.7 kg) who underwent 573 tunneled femoral PICC placements or exchanges from Jan. 1, 2017, to Jan. 31, 2020, were included in the study. All tunneled femoral PICCs were placed using US technique and catheter specifications, including catheter size (French) and length (cm), were retrieved from the electronic medical record. The location of the PICC placement, the number of lumens, the laterality of placement, and the patient's age and weight were also recorded. Only non-mucosal barrier injury CLABSIs, according to the Centers for Disease Control and Prevention (CDC) definitions, were counted as CLABSI for this study. The number of central line days until a CLABSI event was analyzed with an accelerated failure time model using the exponential, Weibull, and log-normal distributions to determine the probability of a CLABSI over time, taking into consideration the recorded covariates.
RESULTS: Tunneled femoral PICC placements accounted for 14,855 line days, during which 20 non-mucosal barrier injury CLABSIs (CLABSI rate of 1.35 per 1,000 line days) occurred during the study period. The highest CLABSI rate occurred in PICCs placed in the neonatal intensive care unit (NICU) at 2.01 per 1,000 line days and the lowest occurred in PICCs placed in interventional radiology at 0.26 per 1,000 line days. Overall, PICCs placed outside of interventional radiology had a CLABSI rate of 1.72 per 1,000 line days. The CLABSI rate during the first 30 days a line was in situ was lower than the rate after 30 days (0.51 per 1,000 line days vs. 3.06 per 1,000 line days, respectively). Statistical modeling and hazard estimation using the Akaike information criterion corrected for small sample size (AICc)-average of log-normal, Weibull and exponential distributions demonstrate the daily risk of CLABSI rapidly increases from day 1 to day 30, with the risk remaining high for the duration of line days.
CONCLUSION: While tunneled femoral PICCs are a relatively safe and effective central venous access alternative, the rate of CLABSI appears to rapidly increase with increasing line days until around day 30 and then remains high thereafter.
引用
- Koo KSH, Cooper AB, Monroe EJ, et al. Line days as a determinant of central line-associated bloodstream infections in pediatric patients with tunneled femoral peripherally inserted central catheters. Pediatr Radiol. 2021. PMID: 33675377. doi:10.1007/s00247-021-05019-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。